Kemwell biopharma announced JV in the United States with Cipla and Manipal Education & Medical Group for Global Development and Commercialisation of Innovative cell therapy products

Mumbai, India, January 08, 2024: Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) has announced a strategic collaboration with Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited, and Manipal Education & Medical Group to incorporate a joint venture in the United States. The primary objective of this joint venture is to develop and commercialize novel Cell therapy products for major unmet medical needs in the United States, Japan, and EU regions and this strategic collaboration is aimed at expediting development, manufacturing, licensing, import and export of cutting-edge Cell therapy products to cater to patients globally.

Commenting on this development, Anurag Bagaria, Chairman and CEO, Kemwell said: “We believe that Cell therapies will become a major branch of medical treatment and will become a standard of care for challenging diseases. Kemwell has built a world-class cGMP facility in Bangalore and made India an emerging hub for “cell therapy development” and manufacturing. The synergistic combinations of Cipla, Manipal and Kemwell will accelerate the development of novel cell-based products for patients and transform the new Joint Venture into a global player in cell therapeutics.”

This marks the second joint venture between Cipla and Kemwell Biopharma, following the incorporation of Aspergen Inc., USA in 2022 for the development, manufacturing, and commercialization of biosimilars for global markets.